New Zealand Pharmaceuticals and Healthcare Report Q2 2016
BMI View: The free reign that New Zealand’s Pharmaceutical Management Agency (PHARMAC) has over
pharmaceutical spending will come under pressure. While the agency’s stringent approach to listing
medicines has helped to curtail drug spending, it has limited access to novel ‘first-in-class’ medicines. This
in turn has created public pressure from both patient groups and politicians that could infringe upon
PHARMAC’s operations. The Trans-Pacific Partnership will also have ramifications on the agency as
stronger biologic protection delays the introduction of biosimilars.
Headline Expenditure Forecasts
? Pharmaceuticals: NZD1.48bn (USD1.0bn) in 2015 to NZD1.51bn (USD932mn) in 2016; 2.0% in local
currency terms and -9.8% in US dollar terms.
? Healthcare: NZD23.09bn (USD16.11bn) in 2015 to NZD23.63bn (USD14.58bn) in 2016; 2.4% in local
currency terms and -9.5% in US dollar terms.
BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (New Zealand 2014-2020) 7
SWOT 9
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (New Zealand 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020) 14
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020) 15
Prescription Drug Market Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 17
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 19
Generic Drug Market Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 21
OTC Medicine Forecast 22
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 23
Pharmaceutical Trade Forecast 24
Table: Pharmaceutical Trade Data And Forecasts (New Zealand 2014-2020) 25
Table: Pharmaceutical Trade Data And Forecasts local currency (New Zealand 2014-2020) 25
Industry Risk Reward Index 26
Asia Pacific Risk/Reward Index 26
New Zealand Risk/Reward Index 32
Rewards 32
Risks 32
Regulatory Review 34
Regulatory Development 34
Intellectual Property Issues 34
Pricing & Reimbursement Regime 35
Table: Top 20 Medicines By Ex-Manufacturer Cost To PHARMAC In The Year Ending June 2010 (NZDmn) 40
Table: Top 20 Medicines Reimbursed By PHARMAC According To Prescription Numbers In The Year Ending June 2010 41
Market Overview 43
Healthcare Sector 44
Table: Healthcare Resources (New Zealand 2010-2015) 45
Table: Healthcare Activity (New Zealand 2010-2015) 46
Table: Healthcare Personnel (New Zealand 2010-2015) 46
Research & Development 47
Clinical Trials 47
Epidemiology 49
Competitive Landscape 53
Research-Based Industry 53
Table: Multinational Market Activity 54
Pharmaceutical Distribution 54
Pharmaceutical Retail Sector 55
Company Profile 57
Douglas Pharmaceuticals 57
New Zealand Pharmaceuticals 60
Pfizer New Zealand 62
Demographic Forecast 64
Table: Population Headline Indicators (New Zealand 1990-2025) 65
Table: Key Population Ratios (New Zealand 1990-2025) 65
Table: Urban/Rural Population & Life Expectancy (New Zealand 1990-2025) 66
Table: Population By Age Group (New Zealand 1990-2025) 66
Table: Population By Age Group % (New Zealand 1990-2025) 67
Glossary 69
Methodology 71
Pharmaceutical Expenditure Forecast Model 71
Healthcare Expenditure Forecast Model 71
Notes On Methodology 72
Risk/Reward Index Methodology 73
Index Overview 74
Table: Pharmaceutical Risk/Reward Index Indicators 74
Indicator Weightings 75
List of Tables
Table: Headline Pharmaceuticals & Healthcare Forecasts (New Zealand 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (New Zealand 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (New Zealand 2014-2020)
Table: Top 20 Medicines By Ex-Manufacturer Cost To PHARMAC In The Year Ending June 2010 (NZDmn)
Table: Top 20 Medicines Reimbursed By PHARMAC According To Prescription Numbers In The Year Ending June 2010
Table: Healthcare Resources (New Zealand 2010-2015)
Table: Healthcare Activity (New Zealand 2010-2015)
Table: Healthcare Personnel (New Zealand 2010-2015)
Table: Multinational Market Activity
Table: Population Headline Indicators (New Zealand 1990-2025)
Table: Key Population Ratios (New Zealand 1990-2025)
Table: Urban/Rural Population & Life Expectancy (New Zealand 1990-2025)
Table: Population By Age Group (New Zealand 1990-2025)
Table: Population By Age Group % (New Zealand 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators